Inzamoda

Enzalutamide, the active ingredient in Inzamoda, is a nonsteroidal antiandrogen presented as a tablet for oral use. It is indicated for the treatment of metastatic castration‑resistant prostate cancer and non‑metastatic castration‑resistant prostate cancer in adult males who have progressed despite hormonal therapy.

GNH USA supplies Inzamoda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to strict quality standards and provides reliable logistics for global distribution to clinical sites and retail pharmacies.

Enzalutamide is used in the hormonal therapy pathway for prostate cancer.

Metastatic castration‑resistant prostate cancer: improves overall survival and delays disease progression. Non‑metastatic castration‑resistant prostate cancer: delays metastasis and extends metastasis‑free survival. Castration‑resistant prostate cancer (general): provides androgen‑receptor blockade when disease progresses despite androgen deprivation therapy.

Adverse reactions may occur with Enzalutamide therapy.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Hot flashes: sudden feeling of warmth and sweating. - Hypertension: elevated blood pressure requiring monitoring. - Diarrhea: loose stools that may affect hydration. - Nausea: mild to moderate upset stomach. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Seizures: rare but potentially life‑threatening events. - Severe hypertension: markedly high blood pressure needing urgent care. - Hepatic injury: elevated liver enzymes or hepatitis. - Interstitial lung disease: inflammation of lung tissue. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: check regularly due to risk of hypertension. Assess seizure history: avoid in patients with prior seizures. Evaluate hepatic function: monitor liver enzymes during treatment. Avoid strong CYP2C8 inhibitors: may increase enzalutamide exposure. Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Enzalutamide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise enzalutamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates (e.g., warfarin): may alter anticoagulant activity. - Anticoagulants (e.g., apixaban, rivaroxaban): monitor for bleeding. - Other antiandrogens (e.g., bicalutamide): may increase toxicity risk.